- Receive exclusive updates during the Winter Games
- Get the inside scoop, event by event
- Hear directly from our Olympic athletes as they chase their dream
- Be able to download photo and video highlights, right to your desktop
Thursday, February 11, 2010
Register with Team USA for tomorrow’s Winter Games
Tomorrow marks the first day of the 2010 Winter Olympic and Paralympic Games in Vancouver, BC. Years of training, hard work, discipline and relentless dedication have given the great athletes of Team USA the right edge to grab that gold. To make sure you keep track of who is skiing the fastest and skating the hardest, register with TeamUSA.org where fans get chance to take part in all of the action. GO USA!
Register at TeamUSA.org and you will:
Tuesday, February 9, 2010
Register at TeamUSA.org for exclusive Winter Games info
Start rockin’ your red white and blue because this Friday marks the beginning of the 2010 Winter Olympic and Paralympic Games in Vancouver, BC. The city will welcome all of the worthy competitors and their diehard fans who are lucky enough to see these world-class athletes live. For those of us who cannot make it to Vancouver and witness the excitement first-hand, TeamUSA.org is giving fans a chance to take part in all the action.Register at TeamUSA.org and you will:
- Receive exclusive updates during the Winter Games
- Get the inside scoop, event by event
- Hear directly from our Olympic athletes as they chase their dream
- Be able to download photo and video highlights, right to your desktop
Sunday, November 15, 2009
Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
Emergent acquires manufacturing facility from MdBio and land from City of Baltimore for $8.2 million
ROCKVILLE, MD, November 13, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.
“Emergent is excited about this new facility in Baltimore because it houses several suites capable of manufacturing multiple products at the same time,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “Accordingly, this facility will provide the flexibility to conduct large-scale manufacturing of rPA while also producing other products in our pipeline.”
Emergent worked closely with the Maryland Department of Business and Economic Development (DBED), MdBio, the City of Baltimore, Baltimore Development Corporation, and other related governmental agencies to complete this transaction.
“Maryland is continuing to strengthen its biotechnology prowess by helping to grow industry leaders like Emergent BioSolutions,” said Governor Martin O’Malley. “The transaction between MdBio and Emergent will maximize the value of the BioProcessing Center by maintaining a bio-manufacturing infrastructure for Maryland’s bioscience community, enabling additional investment to be made in the Center and ensuring that those high paying, highly skilled jobs are created and remain in Maryland.”
Emergent BioSolutions employs over 600 employees across the globe, with over 150 employees located in its corporate headquarters in Rockville and one of its product development sites in Gaithersburg.
“This acquisition reflects our commitment to both continually creating jobs and investing additional capital in the State of Maryland,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “We extend our sincere appreciation to the state and local governments for their ongoing support of our efforts to develop our local manufacturing capabilities and look forward to growing Emergent’s presence in the state.”
Mayor Sheila Dixon, commenting on the announcement, said, “The City of Baltimore is excited about welcoming Emergent BioSolutions to the Baltimore biotech community. With great research institutions such as Johns Hopkins and the University of Maryland as potential partners in the area, we know that Emergent will be a wonderful contributor in the future.”
“Emergent’s decision to expand in Maryland underscores not only our rich research and development environment, but also our mission to support the complete product development life cycle that includes bio manufacturing,” said Maryland Department of Business and Economic Development Secretary Christian S. Johansson. “The Department was pleased to work with MdBio Foundation and the Baltimore Development Corp. to bring this project to fruition.”
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com and www.biothrax.com.
About MdBio Foundation, Inc.
The MdBio Foundation, Inc. is a charitable and educational organization whose mission is to provide and support the State of Maryland’s bioscience community through bioscience awareness, education and workforce development programs including scholarships, post-doctoral conference and career expos, BioGENEius science competition and summer science camps. Since 2003, MdBio has operated the MdBioLab, an educational and well-known mobile bioscience laboratory that visits high schools throughout Maryland to educate youth on biosciences. Over the past six years, MdBioLab has held more than 2,800 classes with 55,000 students and 1,500 teachers. MdBio Foundation became an affiliate of the Tech Council of Maryland in 2006.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2009, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain FDA approval to manufacture products or product candidates in the newly acquired facility; appropriations for BioThrax® procurement; our ability to obtain new BioThrax® sales contracts; our plans to pursue label expansions and improvements for BioThrax®; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the period ended September 30, 2009 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
###
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vhAp658yuc-XrK8amgliY8dj5RM6n0eLlKiw6BN_4NACrr86NRZxwICdNo1FY0fudKO2GVY97rHko3yXmGAAaCgCyMDIhs2zN9uQ4ywf-Dc4jTAEW9DfShSJqF_4O5KjgHMEEG4ZBp3I7HSLZ8eCa8=s0-d)
ROCKVILLE, MD, November 13, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.
“Emergent is excited about this new facility in Baltimore because it houses several suites capable of manufacturing multiple products at the same time,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “Accordingly, this facility will provide the flexibility to conduct large-scale manufacturing of rPA while also producing other products in our pipeline.”Emergent worked closely with the Maryland Department of Business and Economic Development (DBED), MdBio, the City of Baltimore, Baltimore Development Corporation, and other related governmental agencies to complete this transaction.
“Maryland is continuing to strengthen its biotechnology prowess by helping to grow industry leaders like Emergent BioSolutions,” said Governor Martin O’Malley. “The transaction between MdBio and Emergent will maximize the value of the BioProcessing Center by maintaining a bio-manufacturing infrastructure for Maryland’s bioscience community, enabling additional investment to be made in the Center and ensuring that those high paying, highly skilled jobs are created and remain in Maryland.”
Emergent BioSolutions employs over 600 employees across the globe, with over 150 employees located in its corporate headquarters in Rockville and one of its product development sites in Gaithersburg.
“This acquisition reflects our commitment to both continually creating jobs and investing additional capital in the State of Maryland,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “We extend our sincere appreciation to the state and local governments for their ongoing support of our efforts to develop our local manufacturing capabilities and look forward to growing Emergent’s presence in the state.”
Mayor Sheila Dixon, commenting on the announcement, said, “The City of Baltimore is excited about welcoming Emergent BioSolutions to the Baltimore biotech community. With great research institutions such as Johns Hopkins and the University of Maryland as potential partners in the area, we know that Emergent will be a wonderful contributor in the future.”
“Emergent’s decision to expand in Maryland underscores not only our rich research and development environment, but also our mission to support the complete product development life cycle that includes bio manufacturing,” said Maryland Department of Business and Economic Development Secretary Christian S. Johansson. “The Department was pleased to work with MdBio Foundation and the Baltimore Development Corp. to bring this project to fruition.”
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com and www.biothrax.com.
About MdBio Foundation, Inc.
The MdBio Foundation, Inc. is a charitable and educational organization whose mission is to provide and support the State of Maryland’s bioscience community through bioscience awareness, education and workforce development programs including scholarships, post-doctoral conference and career expos, BioGENEius science competition and summer science camps. Since 2003, MdBio has operated the MdBioLab, an educational and well-known mobile bioscience laboratory that visits high schools throughout Maryland to educate youth on biosciences. Over the past six years, MdBioLab has held more than 2,800 classes with 55,000 students and 1,500 teachers. MdBio Foundation became an affiliate of the Tech Council of Maryland in 2006.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2009, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain FDA approval to manufacture products or product candidates in the newly acquired facility; appropriations for BioThrax® procurement; our ability to obtain new BioThrax® sales contracts; our plans to pursue label expansions and improvements for BioThrax®; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the period ended September 30, 2009 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
###
Wednesday, November 11, 2009
Win a Free Roku Player from Motionbox
The rumors are true.... Motionbox is soon to be a featured Channel on the Roku digital video player. You'll be able to hook the player up to your television and enjoy instant access to all the videos you’ve uploaded to Motionbox. All you need is a TV, a high-speed Internet connection (wired or wireless), and a finger to click the remote!As a special sneak preview, we're giving away a few brand new Roku players to people who become Motionbox members this month.
All you have to do is sign up for a FREE Motionbox account before November 30, 2009 then email offers@motionbox.com with subject line "Roku Giveaway" and we'll enter your name for a chance to win a Roku HD Player.
Learn more about Roku:
Read a recent article about Roku.
Check out the Roku website.
Monday, October 19, 2009
Risk of acquiring healthcare-associated infections
When someone develops an infection at a hospital or other patient care facility that they did not have prior to treatment, this is referred to as a healthcare-associated (sometimes hospital-acquired) infection (HAI).Healthcare-associated infections (HAIs) are a global crisis affecting both patients and healthcare workers.
According to the World Health Organization (WHO), at any point in time, 1.4 million people worldwide suffer from infections acquired in hospitals.
A Centers for Disease Control (CDC) report published in March-April 2007 estimated the number of U.S. deaths from healthcare asociated infections in 2002 at 98,987.
The risk of acquiring healthcare-associated infections in developing countries is 2-20 times higher than in developed countries.
Afflicting thousands of patients every year, HAI often leads to lengthening hospitalization, increasing the likelihood of readmission, and adding sizably to the cost of care per patient.
Financially, HAIs represent an estimated annual impact of $6.7 billion to healthcare facilities, but the human cost is even higher.
Until recently, a lack of HAI reporting requirements for healthcare facilities has contributed to less-than-optimal emphasis being placed on eliminating the sources of healthcare associated infections. However, growing public anxiety regarding the issue and resulting legislation on state and local levels demanding accountability is serving to accelerate initiatives to combat HAIs.
To learn more about the impact of healthcare-associated infections for both medical professionals and patients, please visit www.haiwatch.com.
About Not on My Watch Prevention Campaign
To protect patients by reducing the risk of HAI, healthcare professionals must continually update their knowledge of infection management.
As part of an ongoing commitment to quality care and infection prevention, nationwide doctors and hospitals are partnering with Kimberly-Clark to deliver continuing education programs on healthcare-associated infection (HAI) prevention to staff and management. As simple as education sounds, busy doctors and nurses on the front lines of delivering care can find it difficult to find the time to take advantage of scheduled programs within their hospitals.
The HAI Education Program is part of a national infection awareness campaign for healthcare professionals called “Not on My Watch” and will provide the facility with a toolkit that contains informational flyers, patient safety tips and posters.
The "Not on My Watch" campaign provides accredited continuing education (CE) programs based on best practices and guidelines as well as research available on reducing the incidence of healthcare-associated infections.
For details about the "Not On My Watch" campaign, and the HAI Education Bus please visit www.HAIwatch.com.
HAI Education Bus
At Kimberly-Clark, it’s our mission to find innovative ways to develop and maintain a variety of accredited education, equipping healthcare providers with critical insights and information on today’s important clinical issues. That’s why we’re proud to introduce the HAI Education Bus, an impressive new one-of-a-kind mobile classroom that brings accredited CE education right to your door.
Look for this tour bus as it makes its way across the country, delivering education about healthcare-associated infections and other critical healthcare issues from the plains of Texas to the California coast to New York City and places in between.
Types of Healthcare-Associated Infections
Ventilator - Associated Pneumonia (VAP)VAP is the source of the highest morbidity and mortality of all Healthcare Associated Infections.
Read More About VAP
Surgical Site Infections (SSIs)Any breach of patient skin can lead to a surgical site infection.
Read More About SSIs
Cross Contamination (Contact Transfer)Contact transfer (touch contamination) is the number one source of Healthcare Associated Infections.
Read More About Contact Transfer
About HAI Watch
HAI Watch is your resource for collateral and supplies to help keep your organization aware of the importance of healthcare associated infection prevention. The following guidelines on hand hygiene in healthcare settings and other tips are available now, but keep checking back. New HAI awareness tools will be added on an ongoing basis.
About Kimberly-Clark Health Care
At Kimberly-Clark Health Care, we deliver innovative healthcare solutions that you can depend on to meet the demands of your fast-paced world, supported by in-service training, clinical research and accredited education.
Our solutions help you prevent, diagnose, and manage major issues in these clinical areas: Infection Prevention (Protection & Infection Control, Ventilator-Associated Pneumonia and Surgical Site Infections), Digestive Health and Pain Management.
About Kimberly-Clark Corporation
Kimberly-Clark and its well-known global brands are an indispensable part of life for people in more than 150 countries.Every day, 1.3 billion people - nearly a quarter of the world's population - trust K-C brands and the solutions they provide to enhance their health, hygiene and well-being.
With brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend, Kimberly-Clark holds No. 1 or No. 2 share positions in more than 80 countries. To keep up with the latest K-C news and to learn more about the company's 137-year history of innovation, visit www.kimberly-clark.com
Saturday, August 1, 2009
Fuad El-Hibri on Wikipedia
Fuad El-Hibri (born March 2, 1958) is an American businessman, and CEO of Emergent BioSolutions.
Mr.El-Hibri earned a Masters Degree in Public and Private Management from Yale University and a Bachelors Degree with Honors in Economics from Stanford University.
Fuad El-Hibri served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri served as the president of East West Resources Corporation from September 1990 to January 2004.
Mr. El-Hibri was a member of the senior management team of Speywood, LTD., in the United Kingdom. and organized and directed the management buyout of Porton Products Ltd. El-Hibri reorganized Porton, and was advisor to the senior management team involved in the oversight of operations and served as a senior associate and resident project manager at Booz Allen Hamilton and as a manager of Citicorp in New York (Mergers and Acquisitions), and in Jeddah, Saudi Arabia (Operations and Credit).
Mr. El-Hibri has been chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as the chairman of Digicel Holdings from August 2000 to October 2006. He serves as director of Emergent BioDefense Operations Lansing Inc.El-Hibri has been Director and CEO of Emergent BioSolutions since 2004 and He serves as Chairman and Treasurer of El-Hibri Charitable Foundation.
Mr.El-Hibri serves as a member of the board of trustees of American University. He is a member of the board of directors of the International Biomedical Research Alliance (an academic joint venture among the National Institutes of Health, Oxford University and Cambridge University). Mr El-Hibri is also a member of the board of trustees of the National Health Museum.
Mr.El-Hibri earned a Masters Degree in Public and Private Management from Yale University and a Bachelors Degree with Honors in Economics from Stanford University.
Fuad El-Hibri served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri served as the president of East West Resources Corporation from September 1990 to January 2004.
Mr. El-Hibri was a member of the senior management team of Speywood, LTD., in the United Kingdom. and organized and directed the management buyout of Porton Products Ltd. El-Hibri reorganized Porton, and was advisor to the senior management team involved in the oversight of operations and served as a senior associate and resident project manager at Booz Allen Hamilton and as a manager of Citicorp in New York (Mergers and Acquisitions), and in Jeddah, Saudi Arabia (Operations and Credit).
Mr. El-Hibri has been chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as the chairman of Digicel Holdings from August 2000 to October 2006. He serves as director of Emergent BioDefense Operations Lansing Inc.El-Hibri has been Director and CEO of Emergent BioSolutions since 2004 and He serves as Chairman and Treasurer of El-Hibri Charitable Foundation.
Mr.El-Hibri serves as a member of the board of trustees of American University. He is a member of the board of directors of the International Biomedical Research Alliance (an academic joint venture among the National Institutes of Health, Oxford University and Cambridge University). Mr El-Hibri is also a member of the board of trustees of the National Health Museum.
Saturday, July 18, 2009
Fuad El-Hibri is a Washington-Area Success Story
Fuad El-Hibri has served as chief executive officer and as chairman of our board of directors since June 2004 and as president since March 2006. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of our corporate reorganization, BioPort became a wholly owned subsidiary of Emergent. We subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. He served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.
Subscribe to:
Posts (Atom)
